Iliada Bompolaki

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

George Pentheroudakis, Vassiliki Kotoula, Wendy De Roock et al. · BMC Cancer · 2013 · 111 citations · Full text

Medicine, Oncology, Pharmacology +17

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

Anna G. Antonacopoulou, Anastasia G Eleftheraki, Anna Koumarianou et al. · The Pharmacogenomics Journal · 2011 · 75 citations

Medicine, Oncology, Pharmacology +17

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

John Souglakos, Ioannis Boukovinas, Stylianos Kakolyris et al. · Annals of Oncology · 2019 · 47 citations · Full text

Medicine, Oncology, Chemotherapy +12

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group

Elena Fountzilas, Sofia Lampaki, Georgia-Angeliki Koliou et al. · Cancer Immunology Immunotherapy · 2021 · 39 citations · Full text

Life Sciences, Immunology, Oncology +17

Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG)

George Zarkavelis, Vassiliki Kotoula, Georgia-Angeliki Kolliou et al. · ESMO Open · 2019 · 10 citations · Full text

Medicine, Molecular Genetics, Oncology +17